GlassScriptPhysician profile
Emmanuel James Lopp
NPI 1518735547
$2,337.46
in general payments reported to CMS, 2019-2025
16 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.88 · 2024: $849 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $332.28 | 2024-2025 | Fanapt |
| Abbvie INC. | $329.62 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $321.69 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.36 | 2024-2025 | Caplyta |
| Alkermes, INC. | $237.65 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $173.54 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $143.35 | 2024-2025 | Auvelity, Sunosi |
| Corium, LLC | $120.67 | 2024-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $91.87 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $88.04 | 2024 | |
| Collegium Pharmaceutical, INC. | $49.23 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $39.17 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Bausch Health US, LLC | $28.64 | 2025 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $27.61 | 2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $20.86 | 2024 | Invega Sustenna, Invega Trinza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $14.88 | 2023 | Quillichew Er, Quillivant, Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Lopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.